Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_assertion type Assertion NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_head.
- NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_assertion description "[If the correct targets are carefully selected for inhibition in tumors in which the targets are present (clear cell histologic features and loss of VHL expression), then results should resemble those others have observed with targeted therapy, such as the use of STI-571 (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors or anti-HER2/neu (Herceptin; Genentech, South San Francisco, CA) for treatment of breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_provenance.
- NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_assertion evidence source_evidence_literature NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_provenance.
- NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_assertion SIO_000772 14569078 NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_provenance.
- NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_assertion wasDerivedFrom befree-2016 NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_provenance.
- NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_assertion wasGeneratedBy ECO_0000203 NP417564.RADMJSDL-SYbiEVgloxBrXYGPvtOUkMOAq5AvMvJTALxs130_provenance.